In Summer Doldrums, Dx Shops Lose 13.4 Percent in Market Cap Since May | GenomeWeb

It’s been a cruel summer for publicly traded molecular diagnostic companies.

The sector of 111 companies lost 12.5 percent of its combined average market capitalization in July, and 13.4 percent of its market cap during the three months ended July 31, according to a market report issued by Pacific Growth Equities. By comparison, the space fell 9.5 percent for the first seven months of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.